VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
ASM International N.V. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
ASM International N.V.
ASM · Euronext Amsterdam
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into ASM International N.V.'s moat claims, evidence, and risks.
View ASM analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score: both at 74 / 100.
- Segment focus: ASM International N.V. has 3 segments; Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Primary market structure: Quasi-Monopoly vs Oligopoly. Pricing power: n/a vs Moderate.
- Moat breadth: ASM International N.V. has 5 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
ASM International N.V.
ALD equipment
Single-wafer atomic layer deposition (ALD) equipment for semiconductor manufacturing
Global
Semiconductor manufacturers (logic/foundry, memory)
Wafer fab equipment supplier
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
ASM International N.V. strengths
Gilead Sciences, Inc. strengths
Segment mix
ASM International N.V. segments
Full profile >ALD equipment
Quasi-Monopoly
Silicon epitaxy equipment
Oligopoly
Spares and services
Quasi-Monopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.